CTLA4 and neoplasm: Immune checkpoint inhibitors, including nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), atezolizumab (anti-PD-L1), and ipilimumab (anti-CTLA-4), are drugs that block these interactions and “unlock” T cells, thereby allowing them to attack the tumor [12,13].